{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:44:04Z","timestamp":1792467844984,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ekir.2022.01.1055","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T17:23:59Z","timestamp":1643736239000},"page":"688-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Past, Present, and Future of Phosphate Management"],"prefix":"10.1016","volume":"7","author":[{"given":"Simit M.","family":"Doshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-6807","authenticated-orcid":false,"given":"Jay B.","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.01.1055_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192895","article-title":"Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis","volume":"13","author":"Major","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.01.1055_bib4","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.04260413","article-title":"CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis","volume":"8","author":"Block","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib5","series-title":"Number of MBD markers out of range. vol 2021","year":"2021"},{"key":"10.1016\/j.ekir.2022.01.1055_bib6","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00003.2008","article-title":"Increased inorganic phosphate induces human endothelial cell apoptosis in\u00a0vitro","volume":"294","author":"Di Marco","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1159\/000485874","article-title":"High phosphate-induced calcification of vascular smooth muscle cells is associated with the TLR4\/NF-\u03baB signaling pathway","volume":"42","author":"Zhang","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2022.01.1055_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2022.01.1055_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib10","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.01.1055_bib11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.surg.2009.09.024","article-title":"Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism","volume":"146","author":"Heyliger","year":"2009","journal-title":"Surgery"},{"key":"10.1016\/j.ekir.2022.01.1055_bib12","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.108.808733","article-title":"Plasma parathyroid hormone and the risk of cardiovascular mortality in the community","volume":"119","author":"Hagstr\u00f6m","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.01.1055_bib13","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.ki.5001997","article-title":"A\u00a0new era in phosphate binder therapy: what are the options?","author":"Salusky","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2022.01.1055_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1517\/14656566.2016.1133593","article-title":"Phosphate binders, past - present - future. A critical appraisal","volume":"17","author":"Malindretos","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ekir.2022.01.1055_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ki.2009.60","article-title":"Oral phosphate binders","volume":"75","author":"Hutchison","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM197601222940402","article-title":"The dialysis encephalopathy syndrome. Possible aluminum intoxication","volume":"294","author":"Alfrey","year":"1976","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.01.1055_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(83)90014-4","article-title":"Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia","volume":"2","author":"Wills","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.01.1055_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/TCRM.S1555","article-title":"Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate","volume":"4","author":"Mohammed","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ekir.2022.01.1055_bib19","first-page":"314","article-title":"Use of calcium carbonate as a phosphate binder in dialysis patients","volume":"12","author":"Hercz","year":"1986","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.ekir.2022.01.1055_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM198607173150304","article-title":"Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis","volume":"315","author":"Slatopolsky","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.01.1055_bib21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0022-3476(86)81064-2","article-title":"Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis","volume":"108","author":"Salusky","year":"1986","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/nep.12584","article-title":"Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: a systematic review","volume":"21","author":"Rizk","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2022.01.1055_bib23","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.01.1055_bib24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","article-title":"Arterial stiffening and vascular calcifications in end-stage renal disease","volume":"15","author":"Gu\u00e9rin","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.01.1055_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.10.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) [published correction appears in Kidney Int Suppl (2011). 2017;7:e1]","volume":"7","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.ekir.2022.01.1055_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000182446","article-title":"The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis","volume":"30","author":"Guillot","year":"1982","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2022.01.1055_bib28","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"de Francisco","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.01.1055_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107067","article-title":"A\u00a0magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats","volume":"9","author":"Neven","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.01.1055_bib30","series-title":"RENVELA (sevelamer carbonate). Prescribing information","year":"2000"},{"key":"10.1016\/j.ekir.2022.01.1055_bib31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A\u00a0comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.01.1055_bib32","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"8","author":"Ruospo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 9","key":"10.1016\/j.ekir.2022.01.1055_bib33","first-page":"S108","article-title":"Sevelamer worsens metabolic acidosis in hemodialysis patients","volume":"19","author":"De Santo","year":"2006","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib34","first-page":"248","article-title":"Novel dosage forms and regimens for sevelamer-based phosphate binders","volume":"16","author":"Duggal","year":"2006","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib35","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/ndt\/gfp372","article-title":"A\u00a0randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis","volume":"24","author":"Fan","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.01.1055_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.ajkd.2009.10.051","article-title":"A\u00a0randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis","volume":"55","author":"Fishbane","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.01.1055_bib37","series-title":"FOSRENOL (lanthanum carbonate). Prescribing information","year":"2004"},{"key":"10.1016\/j.ekir.2022.01.1055_bib38","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A\u00a0multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","author":"D\u2019Haese","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2022.01.1055_bib39","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000084653","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2022.01.1055_bib40","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","article-title":"Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration [published correction appears in Kidney Int. 2005;68:427]","volume":"67","author":"Lacour","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1525-139X.2006.00169.x","article-title":"Lanthanum: a safe phosphate binder","volume":"19","author":"Persy","year":"2006","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2022.01.1055_bib43","series-title":"VELPHORO (sucroferric oxyhydroxide). Prescribing information","year":"2013"},{"key":"10.1016\/j.ekir.2022.01.1055_bib44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A\u00a0phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib45","series-title":"AURYXIA (ferric citrate) tablets. Prescribing information","year":"2017"},{"key":"10.1016\/j.ekir.2022.01.1055_bib46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bcp.14396","article-title":"Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: a meta-analysis in patients with chronic kidney disease","volume":"87","author":"Choi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib47","first-page":"42","article-title":"Physiological responses of human adults to foods containing phosphate additives","volume":"107","author":"Bell","year":"1977","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/nu9020095","article-title":"Dietary sources of phosphorus among adults in the United States: results from NHANES 2001-2014","volume":"9","author":"McClure","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.ekir.2022.01.1055_bib49","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.2215\/CJN.03950609","article-title":"Phosphorus additives in food and their effect in dialysis patients","volume":"4","author":"Uribarri","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib50","first-page":"91","article-title":"Phosphate-containing prescription medications contribute to the daily phosphate intake in a third of hemodialysis patients","volume":"27","author":"Nelson","year":"2017","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ki.2015.67","article-title":"A\u00a0dearth of data: the problem of phosphorus in prescription medications","volume":"87","author":"Sherman","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib96","series-title":"KAPVAY (clonidine hydrochloride) extended-release tablets, oral. Prescribing information","year":"1974"},{"key":"10.1016\/j.ekir.2022.01.1055_bib97","series-title":"Paxil CR (paroxetine) extended-release tablets, for oral use. Prescribing information","year":"1992"},{"key":"10.1016\/j.ekir.2022.01.1055_bib98","series-title":"NORVASC (amlodipine besylate) tablets for oral administration. Prescribing information","year":"1987"},{"key":"10.1016\/j.ekir.2022.01.1055_bib99","series-title":"PRINIVIL (lisinopril) tablets, for oral use. Prescribing information","year":"1987"},{"key":"10.1016\/j.ekir.2022.01.1055_bib52","series-title":"PhosLo gelcaps (calcium acetate): 667 mg. Prescribing information","year":"2011"},{"key":"10.1016\/j.ekir.2022.01.1055_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1525-139X.2011.00849.x","article-title":"Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose","volume":"24","author":"Daugirdas","year":"2011","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2022.01.1055_bib54","first-page":"522","article-title":"[Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control]","volume":"30","author":"Arenas","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.ekir.2022.01.1055_bib55","first-page":"105","article-title":"Reasons for phosphate binder discontinuation vary by binder type","volume":"24","author":"Wang","year":"2014","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib56","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5414\/CN109057","article-title":"Ferric citrate controls serum phosphorus in dialysis patients: retrospective data","volume":"88","author":"Hain","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib58","first-page":"323","article-title":"Knowledge of phosphorus compared with other nutrients in maintenance dialysis patients","volume":"17","author":"Pollock","year":"2007","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib59","first-page":"220","article-title":"Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia","volume":"14","author":"Cupisti","year":"2004","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib60","first-page":"36","article-title":"The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia","volume":"14","author":"Ford","year":"2004","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2022.01.1055_bib61","first-page":"708","article-title":"Provider attitudes and support of patients\u2019 autonomy for phosphate binder medication adherence in ESRD","volume":"7","author":"Umeukeje","year":"2020","journal-title":"J\u00a0Patient Exp"},{"key":"10.1016\/j.ekir.2022.01.1055_bib62","series-title":"Serum phosphorus (3 month average), categories. Vol 2021","year":"2021"},{"key":"10.1016\/j.ekir.2022.01.1055_bib63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.01.1055_bib64","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(83)90443-2","article-title":"Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency","volume":"85","author":"Davis","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ekir.2022.01.1055_bib65","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","article-title":"Intestinal npt2b plays a major role in phosphate absorption and homeostasis","volume":"20","author":"Sabbagh","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02233563","article-title":"Ionic constituents and osmolality of gastric and small-intestinal fluids after eating","volume":"11","author":"Fordtran","year":"1966","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.ekir.2022.01.1055_bib67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jphp.12999","article-title":"The impact of food intake on the luminal environment and performance of oral drug products with a view to in\u00a0vitro and in silico simulations: a PEARRL review","volume":"71","author":"Pentafragka","year":"2019","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib68","doi-asserted-by":"crossref","first-page":"G233","DOI":"10.1152\/ajpgi.00032.2019","article-title":"Paracellular transport of phosphate along the intestine","volume":"317","author":"Kn\u00f6pfel","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6474","article-title":"Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability","volume":"10","author":"King","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2022.01.1055_bib70","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12281","article-title":"Experimental and regional variations in Na+-dependent and Na+-independent phosphate transport along the rat small intestine and colon","volume":"3","author":"Marks","year":"2015","journal-title":"Physiol Rep"},{"key":"10.1016\/j.ekir.2022.01.1055_bib71","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jbmr.3894","article-title":"Kidney disease progression does not decrease intestinal phosphorus absorption in a rat model of chronic kidney disease-mineral bone disorder","volume":"35","author":"Vorland","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ekir.2022.01.1055_bib72","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.kint.2020.09.035","article-title":"EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients","volume":"99","author":"Hill Gallant","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib73","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/ndt\/gfh781","article-title":"Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure","volume":"20","author":"Eto","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.01.1055_bib74","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth Factor-23 in CKD: the COMBINE trial","volume":"30","author":"Ix","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MNH.0000000000000236","article-title":"Nicotinamide and phosphate homeostasis in chronic kidney disease","volume":"25","author":"Ginsberg","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2022.01.1055_bib76","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A\u00a0randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib77","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib78","doi-asserted-by":"crossref","unstructured":"Chertow GM, Yang Y, Rosenbaum DP. Long-term safety and efficacy of tenapanor for the control of serum phosphorus in patients with chronic kidney disease on dialysis. In American Society of Nephrology (ASN) Kidney Week 2020, Virtual,\u00a02020.","DOI":"10.1681\/ASN.20203110S1166c"},{"key":"10.1016\/j.ekir.2022.01.1055_bib79","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.ekir.2021.06.030","article-title":"Effect of tenapanor on phosphate binder pill burden in hemodialysis patients","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2022.01.1055_bib80","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib81","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib82","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","article-title":"Relation between serum phosphate level and cardiovascular event rate in people with coronary disease [published correction appears in Circulation. 2007;116:e556]","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.01.1055_bib83","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community","volume":"167","author":"Dhingra","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2022.01.1055_bib84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib85","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med. 2008;18:4]","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.01.1055_bib86","article-title":"Association of dyslipidemia with renal outcomes in chronic kidney disease","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.01.1055_bib87","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1185\/030079904X2763","article-title":"The prevalence of anemia in patients with chronic kidney disease","volume":"20","author":"McClellan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2022.01.1055_bib88","doi-asserted-by":"crossref","first-page":"603","DOI":"10.11622\/smedj.2015195","article-title":"Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes","volume":"57","author":"Chuang","year":"2016","journal-title":"Singapore Med J"},{"key":"10.1016\/j.ekir.2022.01.1055_bib89","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.21404","article-title":"Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies","volume":"44","author":"S\u00f8rensen","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ekir.2022.01.1055_bib90","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.ajkd.2020.10.008","article-title":"Design and rationale of HiLo: a pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialysis","volume":"77","author":"Edmonston","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.01.1055_bib91","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.01.1055_bib92","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.V1351307","article-title":"Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial","volume":"13","author":"Paniagua","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib93","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.2008060590","article-title":"Effect of membrane permeability on survival of hemodialysis patients","volume":"20","author":"Locatelli","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1055_bib94","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ki.2011.213","article-title":"The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial","volume":"80","author":"Rocco","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1055_bib95","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922010737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922010737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:39:41Z","timestamp":1762832381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922010737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2468024922010737"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1055","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Past, Present, and Future of Phosphate Management","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}